<DOC>
	<DOCNO>NCT02697292</DOCNO>
	<brief_summary>The purpose study determine whether intravenous immunoglobulin ( IVIG ) treatment reduce significantly number epileptic seizure case autoimmune epileptic seizure .</brief_summary>
	<brief_title>IVIG Patients With VGKC Ab Associated Autoimmune Epilepsy</brief_title>
	<detailed_description>The purpose study determine intravenous immunoglobulin ( IVIG ) treatment significantly reduce number epileptic seizure case autoimmune epilepsy . Potential participant screen outpatient neurology clinic visit appointment . Interested qualify potential participant consent offered participation trial . Once consent obtain , determine participant meet inclusion criterion , participant randomize either IVIG placebo treatment next 5 week . Participants return Mayo Clinic evaluation . Those participant receive placebo 5 week give IVIG open label fashion 5 week ( week 7-11 ) return Mayo Clinic evaluation . All participant receive monthly phone call complete IVIG treatment period 1 year end IVIG 5 week course .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Seropositivity Voltage Gated Potassium Channel Complex ( VGKC ) complex antibody positive LeucineRich , Glioma Inactivated 1 ( LGI1 ) /contactinassociated proteinlike 2 ( CASPR2 ) Antibody cell base assay . And â‰¥ 2 seizure per week ( mean total 1 week ) And duration epilepsy &lt; 3 year Male female age 18 80 year age Women men child bear potential must agree use reliable form contraception throughout course study . Homecare treatment agency available place residence . History thrombotic episode within 2 year prior enrollment Known allergic severe reaction blood product include intolerability previous IVIG Immunoglobulin A ( IgA ) deficiency Prior fail trial high dose steroid ( prednisone &gt; 60mg daily methylprednisolone &gt; 1g weekly &gt; 2 week ) Reproductive status : Women pregnant , Women breastfeed , Women men childbearing potential unwilling unable use acceptable method birth control avoid pregnancy entire study period , evaluate investigator . ( Women nonchildbearing potential history hysterectomy , bilateral oophorectomy , postmenopausal history menstrual flow &gt; 12 month prior screen visit . ) Any surgical procedure ( except minor surgery ) within 4 week prior baseline . Evidence serious uncontrolled concomitant disease may preclude patient participation ( physician determine ) , describe ; Other nervous system disease , cardiovascular disease , hematologic/hematopoiesis disease , respiratory disease , muscular disease , endocrine disease , renal/urologic disease , digestive system disease , congenital acquire severe immunodeficiency Known active infection ( exclude fungal infection nail bed caries dentium ) within 4 week prior baseline . Evidence chronic active hepatitis B C. Active ischemic heart disease past year prior baseline . Patients severe renal hepatic disease ( determined treat physician ) . Severe hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Intravenous Immunoglobulin</keyword>
	<keyword>VGKC</keyword>
	<keyword>Autoimmune epilepsy</keyword>
	<keyword>Gamumex-C</keyword>
</DOC>